Remove Biopharma Remove Doctors Remove Side effects
article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. One aspect that is extremely promising about radiopharmaceutical therapeutics is that they do not give a patient the side effects that are commonly experienced with chemotherapy.

article thumbnail

AUTHENTIC PATIENT VOICE: BOT TO TROT AI Steps Up to Transform Healthcare

PM360

As we enter into the age of precision medicine, AI will be a critical tool to determine, with the help of disease knowledge graphs, which indications, associations, contraindications, side effects, genetic markers, drug targets, drug carriers, and interactions to take into account on a case-by-case basis. AI isn’t coming for your job.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Typically, we think of patient partnerships in terms of their external impact—for example, to help educate doctors and payers. Different patients have unique needs. Anthony Yanni.

article thumbnail

Improving patient access and healthcare literacy [PODCAST]

Clarivate

I worked as a hospital doctor for several years and then as a GP for several years, and it became very apparent that there was not enough information for patients to help them to better understand their illnesses, better understand their treatment [and] what to do with their medications. Dr. Grace Lomax : Yes, happily.